Expression of Concern: Mehra MR et al. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

20 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Adherence with reporting of ethical standards in COVID-19 human studies: a rapid review.BMC medical ethics · 2021
   Pooled it
2. Comparison of infection risks and clinical outcomes in patients with and without SARS-CoV-2 lung infection under renin-angiotensin-aldosterone system blockade: Systematic review and meta-analysis.British journal of clinical pharmacology · 2021
   Pooled it
3. Transparency in the secondary use of health data: assessing the status quo of guidance and best practices.Royal Society open science · 2025
   Article
4. Gene hydrogel platforms for targeted skin therapy: bridging hereditary disorders, chronic wounds, and immune related skin diseases.Frontiers in drug delivery · 2025
   Review
5. Predicting hospital length of stay using machine learning on a large open health dataset.BMC health services research · 2024
   Article
6. Lessons Learned from Coronavirus Disease 2019 (COVID-19) Therapies: Critical Perspectives From the Infectious Diseases Society of America (IDSA) COVID-19 Treatment Guideline Panel.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022
   Article
7. Evolving Acceptance and Use of RWE for Regulatory Decision Making on the Benefit/Risk Assessment of a Drug in Japan.Clinical pharmacology and therapeutics · 2022
   Review
8. Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity.Pharmacological research · 2021
   Review
9. No association between use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEdicaTion (COMET) study.British journal of clinical pharmacology · 2021
   Article
10. How COVID-19 has fundamentally changed clinical research in global health.The Lancet. Global health · 2021
    Review
11. Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review.Clinics (Sao Paulo, Brazil) · 2021
    Review
12. The Pandemic of Publications: Are We Sacrificing Quality for Quantity?Mayo Clinic proceedings · 2020
    Article
13. Letter: online search trends suggest patient concerns around immunosuppression use in inflammatory bowel disease during COVID-19 in the United Kingdom.Alimentary pharmacology & therapeutics · 2020
    Article
14. Proliferation of Papers and Preprints During the Coronavirus Disease 2019 Pandemic: Progress or Problems With Peer Review?Advances in chronic kidney disease · 2020
    Review
15. Is hydroxychloroquine beneficial for COVID-19 patients?Cell death & disease · 2020
    Review
16. An editorial perspective on the infamous COVID-19 studies retracted by Lancet and NEJM.Indian journal of ophthalmology · 2020
    Article
17. Association between chronic ACE inhibitor exposure and decreased odds of severe disease in patients with COVID-19.Anatolian journal of cardiology · 2020
    Article
18. Renin-angiotensin system blockers and susceptibility to COVID-19: a multinational open science cohort study.medRxiv : the preprint server for health sciences · 2020
    Article
19. Gone, but not Forgotten.Cardiac failure review · 2020
    Review
20. Characteristics, laboratories, and prognosis of severe COVID-19 in the Tokyo metropolitan area: A retrospective case series.PloS one · 2020
    Article

Corrections and comments

• ExpressionOfConcernFor
  Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19.2020

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.